These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397 [TBL] [Abstract][Full Text] [Related]
10. Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin's lymphoma. Aref A; Narayan S; Tekyi-Mensah S; Varterasian M; Dan M; Eilender D; Karanes C; al-Katib A Radiat Oncol Investig; 1999; 7(3):186-91. PubMed ID: 10406061 [TBL] [Abstract][Full Text] [Related]
11. Results of radiotherapy and combined modality treatment in early stage high grade non-Hodgkin's lymphoma. Frank C; Flentje M; Goldschmidt H; Hunstein W; Wannenmacher M Strahlenther Onkol; 1994 Jul; 170(7):383-90. PubMed ID: 8052937 [TBL] [Abstract][Full Text] [Related]
12. Treatment results of tonsillar lymphoma: a 10-year experience. Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316 [TBL] [Abstract][Full Text] [Related]
13. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Mauch PM; Kalish LA; Marcus KC; Shulman LN; Krill E; Tarbell NJ; Silver B; Weinstein H; Come S; Canellos GP; Coleman CN Cancer J Sci Am; 1995; 1(1):33-42. PubMed ID: 9166452 [TBL] [Abstract][Full Text] [Related]
14. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737 [TBL] [Abstract][Full Text] [Related]
16. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity]. Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624 [TBL] [Abstract][Full Text] [Related]
17. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223 [TBL] [Abstract][Full Text] [Related]
18. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401 [TBL] [Abstract][Full Text] [Related]
19. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015 [TBL] [Abstract][Full Text] [Related]
20. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study. Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]